Fact based stock research
Marinus Pharmaceuticals (NasdaqGM:MRNS)

US56854Q2003



Research has been discontinued due to acquisition by Immedica.



How to read the free ranks

For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. The higher the rank, the better the stock performs than its peers. And, we do this for six investment strategies:
Value - shows how good of a value the stock is. Green is "inexpensive"; red is "expensive".

Growth - shows a company's growth potential. Green is "high growth" expected; red is "tough times ahead".

Safety - relates to the amount of debt a company has. Green is low debt level; red is high debt level.

Combined Financial - this isn't an average of the first three ranks but rather a consolidated view across several financial indicators. Green = good; red = tread carefully.

(NEW) Sentiment - quantifies professional analyst ratings and holdings as well as market pulse. Green = positive sentiment; red = skepticism (Only available to Premium Subscribers).

(NEW) 360° View - the ultimate rating with all financial and non-financial indicators.

Marinus Pharmaceuticals stock research in summary

marinuspharma.com


n/a
n/a

Latest Obermatt Ranks


Log in or sign up to see the new 360° View and Sentiment ranks.

360° Viewnew
Sentiment Ranknew
Value Rank n/a
Growth Rank n/a
Safety Rank n/a
Combined Rank n/a
Country USA
Industry Pharmaceuticals
Index NASDAQ
Size class X-Small

. Stock data may be delayed. Log in or sign up to get the most recent research.

Add to Watchlist
See Similar Stocks
Subscribe to updates


Multiple opinions. One number.

Analysts rarely agree on a stock’s future. So, who do you believe? Obermatt translates those collective views into a single Sentiment Rank. That plus the financial ranks give you the ultimate 360° View. Sign up to access them.
Why popular stocks have low ratings

It’s easier said than done. When your stock drops, it’s easy to want to sell it and find a better performer. Think twice, or even three times, before trading. Those fees (especially the hidden ones) can eat up your gains.

Review the performance ranks of the individual metrics that form each investment strategy.

Research History: Marinus Pharmaceuticals

RESEARCH HISTORY 2022 2023 2024 2025
VALUE
VALUE 1
10
79
n/a
GROWTH
GROWTH 39
85
53
n/a
SAFETY
SAFETY 59
56
47
n/a
SENTIMENT
SENTIMENT 49
71
16
new
360° VIEW
360° VIEW 13
76
32
new

Most recent update of the stock research: . Financial reporting date used for calculating ranks: . Stock research history is based on the Obermatt Method. The higher the rank, the better Marinus Pharmaceuticals is in the corresponding investment strategy.
Upgrade to a Premium Account to access the latest ranks.


Combined financial peformance in Detail

n/a n/a
RESEARCH HISTORY 2022 2023 2024 2025
VALUE
VALUE 1
10
79
n/a
GROWTH
GROWTH 39
85
53
n/a
SAFETY
SAFETY 59
56
47
n/a
COMBINED
COMBINED 81
56
70
n/a

Last update of combined financial performance: . Stock analysis on combined financial performance: The higher the rank of Marinus Pharmaceuticals the better the performance.


Value Metrics in Detail

n/a n/a
VALUE METRICS 2022 2023 2024 2025
PRICE VS. REVENUES (P/S)
PRICE VS. REVENUES (P/S) 19
13
91
n/a
PRICE VS. PROFITS (P/E)
PRICE VS. PROFITS (P/E) 26
11
11
n/a
PRICE VS. CAPITAL (Market-to-Book)
PRICE VS. CAPITAL (Market-to-Book) 10
11
89
n/a
DIVIDEND YIELD
DIVIDEND YIELD 1
1
1
n/a
CONSOLIDATED RANK: VALUE
CONSOLIDATED RANK: VALUE 1
10
79
n/a

Last update of Value Rank: . Stock analysis on value ratios: The higher the rank, the lower the value ratio of Marinus Pharmaceuticals; except for dividend yield where the rank is higher, the higher the yield.


Growth Metrics in Detail

n/a n/a
GROWTH METRICS 2022 2023 2024 2025
REVENUE GROWTH
REVENUE GROWTH 59
87
80
n/a
PROFIT GROWTH
PROFIT GROWTH 14
1
96
n/a
CAPITAL GROWTH
CAPITAL GROWTH 55
79
26
n/a
STOCK RETURNS
STOCK RETURNS 57
95
5
n/a
CONSOLIDATED RANK: GROWTH
CONSOLIDATED RANK: GROWTH 39
85
53
n/a

Last update of Growth Rank: . Stock analysis on growth metrics: The higher the rank, the higher the growth and returns of Marinus Pharmaceuticals.


Safety Metrics in Detail

n/a n/a
SAFETY METRICS 2022 2023 2024 2025
LEVERAGE
LEVERAGE 100
45
14
n/a
REFINANCING
REFINANCING 57
67
86
n/a
LIQUIDITY
LIQUIDITY 22
35
26
n/a
CONSOLIDATED RANK: SAFETY
CONSOLIDATED RANK: SAFETY 59
56
47
n/a

Last update of Safety Rank: . Stock analysis on safety metrics: The higher the rank, the lower the leverage of Marinus Pharmaceuticals and the more cash is available to service its debt.


Sentiment Metrics in Detail

SENTIMENT 2022 2023 2024 2025
ANALYST OPINIONS
ANALYST OPINIONS n/a
75
7
new
OPINIONS CHANGE
OPINIONS CHANGE 50
50
50
new
PRO HOLDINGS
PRO HOLDINGS 49
55
49
new
MARKET PULSE
MARKET PULSE 14
34
23
new
CONSOLIDATED RANK: SENTIMENT
CONSOLIDATED RANK: SENTIMENT 49
71
16
new

Last update of Sentiment Rank: . Stock analysis on sentiment metrics: The higher the rank, the more positive the sentiment for Marinus Pharmaceuticals.
Upgrade to a Premium Account to access the latest ranks.


Add to Watchlist
See Similar Stocks
Subscribe to updates

Free stock analysis by the purely fact based Obermatt Method for Marinus Pharmaceuticals from February 27, 2025.

Obermatt Portfolio Performance
We’re so convinced about our free research, that we buy our stock tips.
See the performance of the Obermatt portfolio.